and Pfizer Inc

Failures of two Abeta-peptide-targeting antibodies, Eli Lilly and Co.'s solanezumab and Pfizer Inc./Johnson & Johnson/Elan Corp...The company scored a major coup when masitinib outperformed Sutent (sunitinib malate, Pfizer Inc.) in a Phase II head-to-head trial in Gleevec (imatinib, Novartis AG)-resistant GIST

Late Monday, Pfizer Inc

The company was formed in 2008 through a management buyout of the active pharmaceutical ingredients business of Alpharma Inc. (now part of New York-based Pfizer Inc

The company was formed in 2008 through a management buyout of the active pharmaceutical ingredients business of Alpharma Inc. (now part of New York-based Pfizer Inc

Most of Actavis' sales, at this point, derive from generic therapies, including major revenue generators such as those for New York-based Pfizer Inc.'s cholesterol-buster Lipitor (atorvastatin), and for Concerta (methylphenidate hydrochloride), the compound for attention-deficit and hyperactivity disorder from Johnson & Johnson, of New Brunswick, N.J

Inc. (Whitehouse Station, N.J.) Bristol-Myers Squibb Co. (New York) ND Nonexclusive deal to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus Merck will conduct the trial 4/23/13 Merck KGgA (Darmstadt, Germany) Pfizer Inc. (New York) ND Extended collaboration signed in 2002 by Merck's subsidiary EMD Serono Inc...Inc. (Whitehouse Station

Pfizer Inc. (New York) $210 Global collaboration to develop and commercialize multiple Accurins in small-molecule targeted therapies Pfizer took an exclusive option to develop and commercialize multiple Accurins following preclinical research...it also gets research funding and royalties, while BMS holds onto worldwide rights 4/17/13 Tetragenetics Inc. (Cambridge, Mass.) Pfizer Inc. (New York) ND Deal with an option for an exclusive license with Pfizer using Tetragenetics' SionX application of its

In 2007, the company inked a blockbuster deal with Pfizer Inc., of New York, focused on its Gene Expression Modulation by Small-molecules (GEMS) technology platform, which identifies small molecules that regulate post-transcriptional control mechanisms

The company, which originally started out in 1998 and was acquired by Pfizer Inc

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Pearl reported Phase IIb results in 2011 that showed a statistically significant improvement in FEV1 of 47 percent over Foradil (formoterol, Novartis AG) and 49 percent over Spiriva (tiotroprium, Pfizer Inc./Boehringer Ingelheim GmbH) after one week of dosing (p < 0.0001 for both comparisons...Inc., Pfizer Inc., Novartis and AstraZeneca have products in that space

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Ltd. (Tokyo) Tolvaptan A selective vasopressing receptor antagonist Autosomal dominant polycystic kidney disease FDA accepted an NDA 4/15/13 Pfizer Inc. (New York) Xeljanz Tofacitnib citrate Rheumatoid arthritis CHMP adopted a negative opinion 4/29/13 Sanofi Pasteur Ltd. (Lyon, France) Vaxigrip Quadrivalent formulation

Company (Location) Product Description Indication Status Date Pfizer Inc. (New York) Prevenar 13 Pneumococcal polysaccharide conjugate vaccine Infections Phase III data showed it met all primary and secondary objectives focused on immunogenicity, tolerability and safety in adults 18 to 49 4/30/13 Tetraphase Pharmaceuticals Inc. (Watertown, Mass.) Antibiotics Two next-generation antibiotic candidates Community-acquired multidrug-resistant infections Studies demonstrated efficacy 4/30/13 Trius

In the space of a few weeks that year the FDA approved Pfizer Inc.'s targeted therapy Xalkori (crizotinib) to treat certain patients with late-stage, non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene

Company (Location) Product Description Indication Status Date AUTOIMMUNE Rigel Pharmaceuticals Inc. (South San Francisco) and AstraZeneca plc (London) Fostamatinib Oral spleen tyrosine kinase inhibitor Rheumatoid arthritis Missed the X-ray endpoint of modified Total Sharp score, but hit statistical significance in ACR20 scoring, although the Phase III still fell short of those achieved by Pfizer Inc.'s approved Xeljanz 4/8/13 CANCER Array BioPharma Inc. (Boulder, Colo.) ARRY-520 A selective KSP

In a footnote to its recent 10-Q filing, Pfizer Inc